a 2009

The effect of bortezomib on myeloma cell line

POTÁČOVÁ, Anna, Jana ČUMOVÁ, Irena KASALOVÁ, Ondrej ŠEDO, Zbyněk ZDRÁHAL et. al.

Basic information

Original name

The effect of bortezomib on myeloma cell line

Name in Czech

Vliv bortezomibu na myelomové buňky

Authors

POTÁČOVÁ, Anna, Jana ČUMOVÁ, Irena KASALOVÁ, Ondrej ŠEDO, Zbyněk ZDRÁHAL and Roman HÁJEK

Edition

XII. International Myeloma Workshop, 2009

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30200 3.2 Clinical medicine

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

Organization unit

Faculty of Science

ISBN

1557-9190

UT WoS

000268206500217

Keywords (in Czech)

mnohočetný myelom;bortezomib

Keywords in English

multiple myeloma; proteomics;bortezomib
Změněno: 13/3/2009 14:51, Mgr. Anna Potáčová, Ph.D.

Abstract

V originále

Introduction: Multiple myeloma (MM) is still an incurable disease characterized by the clonal expansion of malignant plasma cells. New anticancer drugs further improve prognosis of myeloma patients. The aim of this study was to evaluate changes in protein expression of myeloma cell line ARH 77 after bortezomib treatment. Materials and methods: Myeloma cell line ARH 77 was treated with bortezomib (10 – 40nM) for various periods of time (24 and 48 hours). The proteins contained in total myeloma cell lysate were separated by 2-dimensional polyacrylamide gel electrophoresis (2D-PAGE) and the differentially expressed proteins between the untreated and treated cell lines were excised and identified by mass spectrometry. Results: There were analyzed 94 proteins differentially expressed between treated and control cells; total of 34 protein spots were upregulated: proteins involved in regulation of apoptosis, chaperons/stress related proteins, proteolysis of ubiquitin/protein degradation and cytoskeleton proteins. Sixty protein spots were downregulated: proteins involved in synthesis, regulation of apoptosis, chaperons/stress related proteins, regulation of cell cycle proteins, proteins connected to glycolysis and proteolysis of ubiquitin/protein degradation and antioxidant/redox proteins. Conclusion: We identified 94 proteins altered in myeloma cells after various exposure of to bortezomib. This proteomic approach can contribute to elucidation of mechanisms of new anticancer drugs action.

Links

LC06027, research and development project
Name: Univerzitní výzkumné centrum - Česká myelomová skupina (Acronym: LC MGUS)
Investor: Ministry of Education, Youth and Sports of the CR, University Research Centre - Czech Myeloma Group
MSM0021622434, plan (intention)
Name: Od klasických prognostických markerů ke klinicky aplikovatelným farmakogenomickým a farmakoproteomickým projektům u mnohočetného myelomu a monoklonálních gamapatií
Investor: Ministry of Education, Youth and Sports of the CR, From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies